# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia

> **NCT04045145** · PHASE2 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 8 (actual)

## Conditions studied

- CAH - Congenital Adrenal Hyperplasia

## Interventions

- **DRUG:** Crinecerfont

## Key facts

- **NCT ID:** NCT04045145
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-12
- **Primary completion:** 2021-07-02
- **Final completion:** 2021-07-02
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04045145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04045145, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04045145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*